Erin Wallace

Malignant melanoma is one of the most common primary tumors to spread to the brain.

A sarcoma study arm of the phase II portion of the multiarm PembroPlus clinical trial that combines immunotherapy with chemotherapy has commenced at Cancer Treatment Centers of America (CTCA), Western Regional Medical Center, Goodyear, Arizona

Administering 6 cycles of docetaxel at the beginning of androgen-deprivation therapy (ADT) to patients with metastatic, hormone-sensitive prostate cancer (mHSPC) resulted in a significantly longer overall survival (OS) than ADT alone.

US Veterans, including former Air Force personnel who participated in Operation Ranch Hand, have a 2.4-fold increased risk of multiple myeloma’s precursor state, MGUS,

Former US President Jimmy Carter announced that melanoma was found on four different spots of his brain, as well as on his liver.

Genetic testing may improve treatment for multiple myeloma by helping oncologists identify patients at risk for developing more aggressive disease.

AstraZeneca’s MedImmune has entered into a licensing agreement and collaboration with Inovio Pharmaceuticals, whereby MedImmune was given exclusive rights to Inovio’s INO-3112 immunotherapy.

Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment

Patients with prostate cancer are now more likely to receive appropriate medical care matched to their level of risk, as opposed to overly aggressive or inadequate treatments

A team of scientists at Lawson Health Research Institute recently discovered that ovarian cancer spheroids activate a stress metabolism molecule, LKB1, which is crucial for the survival of ovarian cancer cells.

Data from a phase I/II single-arm trial of the NY-ESO-1 T-Cell Receptor (TCR) therapy, recently published in Nature Medicine, is the first to show feasibility and antitumor responses in patients who have multiple myeloma.

Specific areas in the US may be at health risk due to limited access of specialized gynecologic cancer care.

The cancer drug, FY26, has demonstrated high potency and efficacy compared with cisplatin and other platinum-based chemotherapies